Long-Term Safety of Pegvisomant in Patients with Acromegaly: Comprehensive Review of 1288 Subjects in ACROSTUDY

2012248 citationsJournal Articlebronze Open Access

Authors

A. J. van der Lely · Erasmus University Rotterdam

Beverly M. K. Biller · Massachusetts General Hospital

Thierry Brue · Hôpital de la Timone

Michael Buchfelder · Universitätsklinikum Erlangen

Ezio Ghigo · University of Turin

Roy Gomez · Pfizer (Belgium)

Judith Hey‐Hadavi ·

Abstract

Data entered and evaluated in ACROSTUDY indicate that pegvisomant is an effective and safe medical treatment in patients with acromegaly. The reported low incidence of pituitary tumor size increase, liver enzyme elevations, and lipodystrophy at the injection site are reassuring.

Topics & Keywords

Pituitary Gland Disorders and Treatments Growth Hormone and Insulin-like Growth Factors TGF-β signaling in diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 97, Issue 5, pp. 1589-1597

DOI: 10.1210/jc.2011-2508

Field-Weighted Citation Impact: 17.90